BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 30153862)

  • 1. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.
    Maxwell TJ; Corcoran C; Del-Aguila JL; Budde JP; Deming Y; Cruchaga C; Goate AM; Kauwe JSK;
    Alzheimers Res Ther; 2018 Aug; 10(1):86. PubMed ID: 30153862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
    Han MR; Schellenberg GD; Wang LS;
    BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.
    Deming Y; Li Z; Kapoor M; Harari O; Del-Aguila JL; Black K; Carrell D; Cai Y; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Huang KL; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Kim S; Saykin AJ; De Jager PL; Albert M; Moghekar A; O'Brien R; Riemenschneider M; Petersen RC; Blennow K; Zetterberg H; Minthon L; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Schellenberg G; Haines JL; Mayeux R; Pericak-Vance MA; Farrer LA; Peskind ER; Li G; Di Narzo AF; ; ; Kauwe JS; Goate AM; Cruchaga C
    Acta Neuropathol; 2017 May; 133(5):839-856. PubMed ID: 28247064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.
    Cruchaga C; Kauwe JS; Mayo K; Spiegel N; Bertelsen S; Nowotny P; Shah AR; Abraham R; Hollingworth P; Harold D; Owen MM; Williams J; Lovestone S; Peskind ER; Li G; Leverenz JB; Galasko D; ; Morris JC; Fagan AM; Holtzman DM; Goate AM
    PLoS Genet; 2010 Sep; 6(9):e1001101. PubMed ID: 20862329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
    Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
    Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
    Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
    PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
    Cruchaga C; Kauwe JS; Harari O; Jin SC; Cai Y; Karch CM; Benitez BA; Jeng AT; Skorupa T; Carrell D; Bertelsen S; Bailey M; McKean D; Shulman JM; De Jager PL; Chibnik L; Bennett DA; Arnold SE; Harold D; Sims R; Gerrish A; Williams J; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Haines JL; Mayeux R; Pericak-Vance MA; Farrer LA; Schellenberg GD; Peskind ER; Galasko D; Fagan AM; Holtzman DM; Morris JC; ; ; ; Goate AM
    Neuron; 2013 Apr; 78(2):256-68. PubMed ID: 23562540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
    Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
    J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
    Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
    J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Ramos de Matos M; Ferreira C; Herukka SK; Soininen H; Janeiro A; Santana I; Baldeiras I; Almeida MR; Lleó A; Dols-Icardo O; Alcolea D; Benussi L; Binetti G; Paterlini A; Ghidoni R; Nacmias B; Meulenbroek O; van Waalwijk van Doorn LJC; Kuiperi HBJ; Hausner L; Waldemar G; Simonsen AH; Tsolaki M; Gkatzima O; Resende de Oliveira C; Verbeek MM; Clarimon J; Hiltunen M; de Mendonça A; Martins M
    J Alzheimers Dis; 2018; 66(2):639-652. PubMed ID: 30320580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex-specific genetic predictors of Alzheimer's disease biomarkers.
    Deming Y; Dumitrescu L; Barnes LL; Thambisetty M; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Huentelman M; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Moghekar A; Del Aguila JL; Fernandez MV; Budde J; Hassenstab J; Fagan AM; Riemenschneider M; Petersen RC; Minthon L; Chao MJ; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Peskind ER; Li G; Davis LK; Sealock JM; Cox NJ; ; ; Goate AM; Bennett DA; Schneider JA; Jefferson AL; Cruchaga C; Hohman TJ
    Acta Neuropathol; 2018 Dec; 136(6):857-872. PubMed ID: 29967939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.
    Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM;
    Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.
    Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M
    J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
    Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42.
    Sleegers K; Bettens K; De Roeck A; Van Cauwenberghe C; Cuyvers E; Verheijen J; Struyfs H; Van Dongen J; Vermeulen S; Engelborghs S; Vandenbulcke M; Vandenberghe R; De Deyn PP; Van Broeckhoven C;
    Alzheimers Dement; 2015 Dec; 11(12):1452-1460. PubMed ID: 26086184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.
    Jansen IE; van der Lee SJ; Gomez-Fonseca D; de Rojas I; Dalmasso MC; Grenier-Boley B; Zettergren A; Mishra A; Ali M; Andrade V; Bellenguez C; Kleineidam L; Küçükali F; Sung YJ; Tesí N; Vromen EM; Wightman DP; Alcolea D; Alegret M; Alvarez I; Amouyel P; Athanasiu L; Bahrami S; Bailly H; Belbin O; Bergh S; Bertram L; Biessels GJ; Blennow K; Blesa R; Boada M; Boland A; Buerger K; Carracedo Á; Cervera-Carles L; Chene G; Claassen JAHR; Debette S; Deleuze JF; de Deyn PP; Diehl-Schmid J; Djurovic S; Dols-Icardo O; Dufouil C; Duron E; Düzel E; ; Fladby T; Fortea J; Frölich L; García-González P; Garcia-Martinez M; Giegling I; Goldhardt O; Gobom J; Grimmer T; Haapasalo A; Hampel H; Hanon O; Hausner L; Heilmann-Heimbach S; Helisalmi S; Heneka MT; Hernández I; Herukka SK; Holstege H; Jarholm J; Kern S; Knapskog AB; Koivisto AM; Kornhuber J; Kuulasmaa T; Lage C; Laske C; Leinonen V; Lewczuk P; Lleó A; de Munain AL; Lopez-Garcia S; Maier W; Marquié M; Mol MO; Montrreal L; Moreno F; Moreno-Grau S; Nicolas G; Nöthen MM; Orellana A; Pålhaugen L; Papma JM; Pasquier F; Perneczky R; Peters O; Pijnenburg YAL; Popp J; Posthuma D; Pozueta A; Priller J; Puerta R; Quintela I; Ramakers I; Rodriguez-Rodriguez E; Rujescu D; Saltvedt I; Sanchez-Juan P; Scheltens P; Scherbaum N; Schmid M; Schneider A; Selbæk G; Selnes P; Shadrin A; Skoog I; Soininen H; Tárraga L; Teipel S; ; Tijms B; Tsolaki M; Van Broeckhoven C; Van Dongen J; van Swieten JC; Vandenberghe R; Vidal JS; Visser PJ; Vogelgsang J; Waern M; Wagner M; Wiltfang J; Wittens MMJ; Zetterberg H; Zulaica M; van Duijn CM; Bjerke M; Engelborghs S; Jessen F; Teunissen CE; Pastor P; Hiltunen M; Ingelsson M; Andreassen OA; Clarimón J; Sleegers K; Ruiz A; Ramirez A; Cruchaga C; Lambert JC; van der Flier W
    Acta Neuropathol; 2022 Nov; 144(5):821-842. PubMed ID: 36066633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.